PCSK9 and familial hyperaldosteronism: In fact, Mandraffino et al. recently showed that PCSK9-i significantly reduced PWV compared to ezetimibe in a cohort of FH subjects with or without ASCVD; furthermore, Cicero et al. found a significant reduction of PWV already after three months of PCSK9-i medication.